为提高我国胰腺癌的总体治疗水平,中华医学会外科学分会胰腺外科学组、中国研究型医院学会胰腺疾病专业委员会组织相关专家制定了本指南。本指南基于推荐分级的评价、制定与评估(Grading of Recommendations Assessment,Development and...为提高我国胰腺癌的总体治疗水平,中华医学会外科学分会胰腺外科学组、中国研究型医院学会胰腺疾病专业委员会组织相关专家制定了本指南。本指南基于推荐分级的评价、制定与评估(Grading of Recommendations Assessment,Development and Evaluation,GRADE)系统,针对胰腺癌新辅助治疗的应用指征、方案选择、疗效评估及其相关病理学诊断、手术策略等热点问题展开讨论,对现有临床研究的证据等级量化评估并提出推荐意见,以指导并促进胰腺癌新辅助治疗的临床实践。本指南强调多学科综合治疗协作组的重要地位,体现出胰腺癌治疗理念的转变。新辅助治疗能够有效延长部分胰腺癌患者的生存期,但仍需开展高质量临床研究,以进一步提升证据等级,完善临床实践方案,改善患者预后。展开更多
Aiming to keep pace with the renewal of international guidelines and refine the domestic treatment system of pancreatic cancer,the Chinese Pancreatic Surgery Association,Chinese Medical Association and Pancreatic Dise...Aiming to keep pace with the renewal of international guidelines and refine the domestic treatment system of pancreatic cancer,the Chinese Pancreatic Surgery Association,Chinese Medical Association and Pancreatic Disease Committee of China Research Hospital Association launched this Chinese guidelines for neoadjuvant therapy of pancreatic cancer(2020 edition).Based on the Grading of Recommendations Assessment,Development,and Evaluation system,the guidelines have conducted a discussion on the indication,regimen selection,therapeutic effect evaluation,pathological diagnosis,surgery strategy,etc.The guidelines have quantified the evidence level of the current clinical researches and provided recommendations for the clinical practice in neoadjuvant therapy of pancreatic cancer.The guidelines have highlighted the role of multiple disciplinary team and represented the conversion of treatment concepts in pancreatic cancer.Neoadjuvant therapy has prolonged the survival of part of pancreatic cancer patients.However,more high-quality clinical researches are in urgent need to improve the level of evidence,optimize the clinical practice,and improve the survival of patients.展开更多
文摘为提高我国胰腺癌的总体治疗水平,中华医学会外科学分会胰腺外科学组、中国研究型医院学会胰腺疾病专业委员会组织相关专家制定了本指南。本指南基于推荐分级的评价、制定与评估(Grading of Recommendations Assessment,Development and Evaluation,GRADE)系统,针对胰腺癌新辅助治疗的应用指征、方案选择、疗效评估及其相关病理学诊断、手术策略等热点问题展开讨论,对现有临床研究的证据等级量化评估并提出推荐意见,以指导并促进胰腺癌新辅助治疗的临床实践。本指南强调多学科综合治疗协作组的重要地位,体现出胰腺癌治疗理念的转变。新辅助治疗能够有效延长部分胰腺癌患者的生存期,但仍需开展高质量临床研究,以进一步提升证据等级,完善临床实践方案,改善患者预后。
文摘Aiming to keep pace with the renewal of international guidelines and refine the domestic treatment system of pancreatic cancer,the Chinese Pancreatic Surgery Association,Chinese Medical Association and Pancreatic Disease Committee of China Research Hospital Association launched this Chinese guidelines for neoadjuvant therapy of pancreatic cancer(2020 edition).Based on the Grading of Recommendations Assessment,Development,and Evaluation system,the guidelines have conducted a discussion on the indication,regimen selection,therapeutic effect evaluation,pathological diagnosis,surgery strategy,etc.The guidelines have quantified the evidence level of the current clinical researches and provided recommendations for the clinical practice in neoadjuvant therapy of pancreatic cancer.The guidelines have highlighted the role of multiple disciplinary team and represented the conversion of treatment concepts in pancreatic cancer.Neoadjuvant therapy has prolonged the survival of part of pancreatic cancer patients.However,more high-quality clinical researches are in urgent need to improve the level of evidence,optimize the clinical practice,and improve the survival of patients.
